U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129187) titled 'SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response' on Aug. 01.
Brief Summary: This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant TCbHP regimen. Patients with <50% tumor shrinkage or persistent nodal positivity after 4 cycles of TCbHP will switch to SHR-A1811 for 4 cycles (cycles 5-8).
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Early Breast Cancer
HER2 + Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer...